New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
12:18 EDTGILDGilead announces 24-week Phase 2 results for once-daily HIV regimen
Gilead Sciences announced detailed 24-week results from a Phase 2 study evaluating a once-daily single tablet regimen containing tenofovir alafenamide for the treatment of HIV-1 infection. A regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg was found to be similar to Stribild based on the percentage of patients with HIV RNA levels less than 50 copies/mL at 24 weeks of treatment. These findings were presented today in a latebreaker session at the 20th Conference on Retroviruses and Opportunistic Infections taking place in Atlanta. In Study 102, HIV-positive treatment-naÔve adult patients were randomized to receive the investigational TAF-based regimen or Stribild. At 24 weeks, 87% of patients taking TAF and 90% of patients taking Stribild achieved HIV RNA less than 50 copies/mL, based on the FDA snapshot algorithm. There were no statistically significant differences in the frequency and nature of Grades 3-4 laboratory abnormalities, and the frequency and nature of adverse events were similar between the two arms. Both regimens were generally well tolerated.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:08 EDTGILDAmerican Society for Clinical Pharmacology and Therapeutics holds meeting
Subscribe for More Information
March 2, 2015
09:34 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL MNTA CELG TSLA MCD ARUN GILD KO TWTR NFLX
February 27, 2015
07:37 EDTGILDGilead removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
February 26, 2015
19:09 EDTGILDGilead announces Phase 3 results for once-daily single tablet HIV regimen
Gilead Sciences announced detailed 48-week results from two Phase 3 studies, Studies 104 and 111, evaluating its investigational once-daily single tablet regimen containing tenofovir alafenamide, or TAF, for the treatment of HIV-1 infection in treatment-naÔve adults. A regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg was found to be statistically non-inferior to Gileadís Stribild, containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. A second analysis found that patients receiving the TAF regimen also had significantly better renal and bone laboratory parameters than those treated with Stribild. The data were presented in two late-breaker presentations at the 22nd Conference on Retroviruses and Opportunistic Infections in Seattle.
15:25 EDTGILDGilead announces 96% SVR12 rate in Phase 3 study of Harvoni
Subscribe for More Information
February 25, 2015
15:30 EDTGILDGilead announces preclincal data on investigational TLR7 agonist
Subscribe for More Information
February 24, 2015
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
February 23, 2015
16:00 EDTGILDOptions Update; February 23, 2015
Subscribe for More Information
09:39 EDTGILDActive equity options trading on open
Subscribe for More Information
07:16 EDTGILDMylan signs exclusive agreement with Gilead to distribute Solvaldi, Harvoni
Subscribe for More Information
February 19, 2015
09:35 EDTGILDOption volume leaders
Option volume leaders: AAPL TSLA TWTR MCD WMT PBR SPWR WFM GILD FB SCTY according to Track Data.
February 18, 2015
09:37 EDTGILDOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use